Food Allergies | Causes, Symptoms & Treatment | ACAAI Public Website
A Food-Allergy Fix Hiding In Plain Sight
Tami McGraw used to be so allergic to red meat that even fumes from cooking might send her into anaphylactic shock. She couldn't fry sausages for her family. She couldn't go to cookouts with friends. Once, she passed out driving home with her son after accidentally inhaling fumes while volunteering at the school cafeteria. "That's the closest I came to dying," she told me. Every whiff of sizzling meat, every journey out of the house came spring-loaded with danger.
The episode in the school cafeteria rattled McGraw so much that she brought up with her allergist a then-unorthodox therapy called Xolair. Xolair is a bimonthly or monthly injection originally approved in 2003 for asthma, which McGraw has been diagnosed with. But doctors had long suspected that Xolair could do more, and they had already started noticing an intriguing curious side effect in asthma patients: Their allergic reactions to food were diminished too.
McGraw's doctor agreed to prescribe her Xolair—officially for asthma but unofficially with the hope of treating her allergy. Soon, she found she could cook red meat in the house again. Then, she could eat it. She had a bite of bacon, a bite of hamburger. All good. McGraw still doesn't care for red meat—doctors recommend continuing avoidance, and she had developed a distaste after her allergic reactions anyway—but she no longer worries about a cross-contaminated utensil or fumes lingering in the air. "I could go in places without fear," she said. "I could go out to eat." Since 2016, she has been living, in other words, a pretty normal life.
Earlier this year—more than 20 years after Xolair first came to market and eight years after it transformed McGraw's life—Xolair was approved for food allergies. The drug is finally available to the millions of Americans with severe, sometimes-fatal allergic reactions. Rates of food allergies have been rising this entire time, nearly doubling in children since Xolair was initially developed. Though it is not meant to be a cure, the drug provides enough protection against accidental exposure to bring tremendous relief.
"It's a complete life-changer," says Robert Wood, a pediatric allergist at Johns Hopkins who co-led the study that recently got Xolair green-lighted for food allergies. And it's been a long time coming.
Xolair works by intercepting immune molecules called IgE, known to be a trigger in allergic reactions. For this reason, its potential to calm food allergies was apparent from the very beginning, but a frustrating series of events in the 2000s kept drugs like it out of many patients' reach.
First, a similar drug that was ahead of Xolair in development was unceremoniously shelved in 2004—despite promising results in treating peanut allergy—as the result of a bitter legal battle between its manufacturer and Xolair's. This cleared the path for Xolair, which suffered a different setback: Its clinical trial for peanut allergy was terminated early in 2006 for safety reasons unrelated to the drug itself. Two children had severe reactions when they were being "challenged" with peanuts to gauge the extent of their allergy. Xolair's manufacturer deemed the peanut challenges, and therefore the whole trial, too risky. The incomplete results from the study, when they were published, nevertheless looked encouraging.
Throughout this period, Xolair was available to patients with asthma, and in 2014, it was also approved for idiopathic, or unexplained, chronic hives. Both of these conditions tend to involve high levels of IgE, the molecule that Xolair blocks. They often overlap with food allergies, says Scott Commins, an allergist at the University of North Carolina, who is also McGraw's doctor. This led to a two-tier system: Commins could offer Xolair to food-allergy patients who, like McGraw, also had asthma or chronic hives. Patients who didn't have multiple conditions were out of luck. They could get Xolair off-label, but few could afford it. Insurance companies do not cover off-label prescriptions, and the list price runs $30,000 to $60,000 a year. "We were definitely not able to use it as much as we wanted," Commins told me.
To secure FDA approval and insurance coverage of Xolair for food allergies, patients needed more than promising preliminary data and anecdotal stories: They needed a big, definitive clinical trial. In 2019, Wood and other researchers finally secured the funding for such a trial, dubbed OUtMATCH, which was a collaboration between the National Institute of Allergy and Infectious Diseases and Xolair's manufacturers. The results of the first of its three stages were published this February: After 16 weeks on Xolair, two-thirds of participants allergic to peanuts and at least two other foods (such as milk and eggs) were able to eat the equivalent of two and a half peanuts. A similar proportion could eat their other allergy foods too. This study persuaded the FDA to approve the drug for food allergies.
Xolair is most life-changing for patients with allergies that are difficult to avoid—either because their allergen is rarely labeled or because they react to even trace amounts, or both. That includes people like McGraw, and it includes people like Christine Robinson, whom I interviewed five years ago about her corn allergy. Chemicals derived from corn, it turns out, are hidden just about everywhere in processed food: Robinson would react to bottled water, iced tea, table salt, bagged salads, frozen fish, the wax on apples and oranges. She went out with an armament of Benadryl, Zantac, prednisone, and EpiPens, the last of which delivers a jolt of emergency epinephrine to counteract anaphylaxis. Since we first talked, she has also started Xolair. "It's amazing, really," she told me recently. She still doesn't eat corn, but her reactivity is much lower. "The reactions are not an emergency now; they are an annoyance." Recently, her EpiPen expired before she had occasion to use it.
Patients with only mild allergies, on the other hand, might not find an injection every two or four weeks worth the trouble. And Xolair did not work as well for one-third of people in the trial. Predicting who will or will not respond to Xolair and understanding why is one of the big remaining questions ahead, says Scott Sicherer, an allergist at Mount Sinai and a principal investigator on the OUtMATCH trial.
Xolair also has the practical advantage of treating multiple food allergies at once, says Stacie Jones, a pediatric allergist at Arkansas Children's Hospital who is also part of the OUtMATCH study. The only other treatment available, oral immunotherapy, is food specific: Patients ingest a tiny daily amount of their allergy food, gradually upping the dose over time until they reach a maintenance dose. An oral immunotherapy for peanuts called Palforzia is approved, and some allergy doctors now offer custom regimens for a number of foods. But the process can be arduous, and patients with multiple allergies generally need to go through it for each food.
Xolair and oral immunotherapy potentially could be used together. The second of the three stages of the OUtMATCH trial was designed to investigate whether adding Xolair can make oral immunotherapy safer and more effective. The third stage follows participants after they discontinue Xolair, and as some reincorporate allergy foods back into their diet. "What we're learning in the clinic and in the study is that most people can actually start to eat the food they're allergic to," Wood told me, adding that the results would be published in the coming months. The data, if convincing, could dramatically change how Xolair is used—the drug is currently approved only alongside strict avoidance.
In our conversation, Wood also evinced more than a hint of impatience about the two decades needed to make Xolair available for food allergies in the first place. "It's honestly quite ridiculous that it took this long," he told me. "But at least we're here now."
Food Allergy Treatment Market Share Forecasts To Reach USD 13.4 Billion By 2034, At 8.9% CAGR: Prophecy Market Insights
PMI
"Food Allergy Treatment Market" from 2024-2034 with covered segments By Food Source (Peanut Allergies, Tree Nut Allergies, Dairy Product Allergies, and Others), By Allergic Reaction (Immunoglobulin E (IgE) Mediated, and Non-IgE Mediated), By Diagnosis Tests (Skin Prick Test(SPT), Blood Test, Oral Food Challenge (OFC) and Others), By Treatment Type (Antihistamines, Oral Immunotherapy (OIT), Epinephrine Auto-Injectors (EpiPens), Other Treatments), By End-Use (Hospitals and Clinics, Ambulatory Care Settings, Home Care), and By Regional Forecast, (2024-2034), which provides the perfect mix of market strategies, and industrial expertise with new cutting-edge technology to give the best experience.
Covina, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Prophecy Market Insights forecasts that the global food allergy treatment market size and share will grow from USD 6.15 Billion in 2024 to USD 13.4 Billion by 2034, driven by a compound annual growth rate (CAGR) of 8.9% throughout the forecast period.
Food Allergy Treatment Market Report Overview
Food Allergy Treatment is a rapidly evolving field focused on managing and potentially curing adverse immune responses triggered by specific foods. Food allergies can cause a wide range of symptoms, from mild reactions like hives and gastrointestinal discomfort to severe, life-threatening anaphylaxis.
Common allergens include peanuts, tree nuts, shellfish, milk, eggs, wheat, soy, and fish. The rising prevalence of food allergies, particularly among children, has driven significant advancements in both the diagnosis and treatment of these conditions. Treatments range from allergen avoidance and emergency interventions to emerging therapies such as oral immunotherapy (OIT) and biologics designed to desensitize the immune system.
Download a Free Sample Research Report with Latest Industry Insights: https://www.Prophecymarketinsights.Com/market_insight/Insight/request-sample/5477
Our Free Sample Report includes:
Overview & introduction of market study
Revenue and CAGR of the market
Drivers & Restrains factors of the market
Major key players in the market
Regional analysis of the market with a detailed graph
Detailed segmentation in tabular form of market
Recent developments/news of the market
Opportunities & Challenges of the Market
Competitive Landscape:
The Food Allergy Treatment Market is characterized by rapid growth, technological innovation, and fierce competition. Companies are expanding their global presence, focusing on sustainability, and diversifying their service offerings to stay competitive.
Story continues
Some of the Key Market Players:
Johnson & Johnson
Sanofi
Novartis Pharmaceuticals
Aimmune Therapeutics
DBV Technologies
Regeneron Pharmaceuticals
Thermo Fisher Scientific
ALK Abello
Mast Group
Food Allergy Research & Education (FARE)
Asthma and Allergy Foundation of America (AAFA)
To Know More on Additional Market Players, Download a Free Sample Report Here: https://www.Prophecymarketinsights.Com/market_insight/Insight/request-pdf/5477
Analyst View:
The target market is characterized by a shift from traditional management practices like strict allergen avoidance and emergency treatment to proactive and preventive approaches that aimed at desensitizing patients and potentially offering long-term solutions. This shift is supported by substantial investments in research and development, particularly in immunotherapy and biologics, which are expected to transform the treatment landscape.
Market Dynamics:
Drivers:
Advancements in Immunotherapy
Immunotherapy is emerging as a promising approach in food allergy treatment offering potential long-term solutions by gradually desensitizing patients to specific allergens. Techniques such as oral immunotherapy (OIT), sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT) are gaining traction as they show efficacy in reducing allergic reactions.
Request for a Discounted Price on this Report @ https://www.Prophecymarketinsights.Com/market_insight/Insight/request-discount/5477
Market Trends:
Personalized Medicine and Targeted Therapies
The trend toward personalized medicine is significantly impacting the Food Allergy Treatment Market. Advances in genetic testing and biomarker identification are enabling more targeted approaches to treatment, allowing for therapies that are tailored to the specific needs of individual patients.
Segmentation:
Food Allergy Treatment Market is segmented based on Food Source, Allergic Reaction, End-User, and Region.
Food Source Insights
Allergic Reaction Insights
End-User Insights
Request a Customized Copy of Report @ https://www.Prophecymarketinsights.Com/market_insight/Insight/request-customization/5477
Recent Development:
In February 2024, The FDA approved Xolair injection for the treatment of immunoglobulin E-mediated food allergies in healthy adults and children one year of age and older. This medication reduces the risk of allergic reactions (Type I), which include anaphylaxis, that can happen when a person unintentionally comes into contact with certain foods. Allergy-related foods must still be avoided by patients using Xolair. Xolair is not approved to treat allergic reactions, including anaphylaxis, right away. It is intended to be used frequently to reduce the chance of allergic reactions.
Regional Insights
North America: In this region the target market is highly developed and characterized by a sophisticated healthcare infrastructure and advanced diagnostic and therapeutic options.
Asia Pacific: The market in this region is characterized by a growing adoption of advanced diagnostic techniques and treatments, including allergy medications, immunotherapy, and emerging biologic therapies.
Browse Detail Report on "Food Allergy Treatment Market Size, Share, By Food Source (Peanut Allergies, Tree Nut Allergies, Dairy Product Allergies, and Others), By Allergic Reaction (Immunoglobulin E (IgE) Mediated, and Non-IgE Mediated), By Diagnosis Tests (Skin Prick Test(SPT), Blood Test, Oral Food Challenge (OFC) and Others), By Treatment Type (Antihistamines, Oral Immunotherapy (OIT), Epinephrine Auto-Injectors (EpiPens), Other Treatments), By End-Use (Hospitals and Clinics, Ambulatory Care Settings, Home Care), and By Region - Trends, Analysis, and Forecast till 2034" with complete TOC @ https://www.Prophecymarketinsights.Com/market_insight/food-allergy-treatment-market-5477
About Us:
Prophecy Market Insights is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
Prophecy's expertize area covers products, services, latest trends, developments, market growth factors, and challenges along with market forecast in various business areas such as Healthcare, Pharmaceutical, Biotechnology, Information Technology (IT), Automotive, Industrial, Chemical, Agriculture, Food and Beverage, Energy, and Oil and Gas. We also offer various other services such as, data mining, information management, and revenue enhancement suggestions.
Contact Us:
Prophecy Market Insights
US: 964 E. Badillo Street
#2042 Covina,
CA 91724
US toll-free: +1 860 531 2574
Rest of World: + 91 7775049802
Follow us on LinkedInTwitter
View comments
Pictures, Causes, And Treatment For Scaly Skin
Several skin disorders and physical conditions can lead to scaling on your top layer of skin. These may include:
Irritant contact dermatitis
Contact dermatitis doesn't necessarily involve an allergic reaction. It typically develops when skin cells become damaged or irritated due to contact with toxic or irritating substances, like solvents, scratchy fabrics, or hair dye. Symptoms can include:
Allergic eczema
Allergic eczema is a delayed allergic reaction that occurs about 24 to 48 hours after making direct contact with an allergen, such as jewelry, plants, or fragrances. Symptoms can include:
Allergic reaction
An allergic reaction to food or airborne substances like mold or pollen can trigger a skin rash. Usually, the first time you experience an allergic reaction, the symptoms are more mild. However, if repeated exposure occurs, it can become severe or life threatening. Symptoms can include:
When it's an emergency
Severe and sudden allergic reactions may cause swelling and difficulty breathing that require emergency medical attention. Contact 911 or your local emergency services.
Drug allergy
An allergic reaction to a drug may cause symptoms that can occur 1 day to 3 weeks after taking it for the first time. Symptoms can include:
Chronic drug rashes, such as eczematous drug eruptions or lichenoid drug eruptions, can be scaly.
When it's an emergency
A drug allergy can potentially cause a severe allergic reaction. Contact 911 or your local emergency services if you experience symptoms that include:
Athlete's foot (tinea pedis)
Athlete's foot is a fungal infection that usually affects the feet and toenails. It can be difficult to treat in people with weakened immune systems. Symptoms of athlete's foot can include:
Some people with athlete's foot may also experience onychomycosis, which causes discolored, thick, or crumbling toenails.
Ringworm (tinea corporis)
Ringworm is a fungal infection that can appear on the body or scalp. Symptoms may include:
Eczema (atopic dermatitis)
Eczema tends to occur as a chronic condition. People may have flare-ups due to triggers that cause the immune system to overreact. Symptoms can include:
Psoriasis
Psoriasis is a chronic skin condition that typically causes skin cells to build up faster than they should. It tends to affect the scalp, elbows, knees, and lower back. It can also affect the joints, which is known as psoriatic arthritis. The symptoms of psoriasis may include:
Seborrheic dermatitis
Seborrheic dermatitis may develop due to excess oil production that irritates the skin. It tends to affect the scalp but can also affect the body. Symptoms can include:
Actinic keratosis (sun spots)
Actinic keratosis is a common precancerous skin condition that usually occurs due to long-term exposure to sunlight. Symptoms can include:
Ichthyosis vulgaris
Ichthyosis vulgaris is a skin condition in which the skin doesn't shed dead skin cells. Symptoms can include:
Hypoparathyroidism
Hypoparathyroidism occurs when the parathyroid glands in the neck don't produce enough parathyroid hormone, causing low levels of calcium and high levels of phosphorus in the body. Symptoms can include:
Kawasaki disease (mucocutaneous lymph node syndrome)
Kawasaki disease causes inflammation in the arteries, veins, and capillaries. It's also the most common cause of acquired heart disease and tends to affect children under 5. Symptoms may include:
When to get medical attention
Kawasaki disease can cause serious heart problems. It's best to get medical attention if you suspect your child has it.
Toxic shock syndrome
Toxic shock syndrome occurs when a bacterial infection enters the bloodstream, where it produces toxins that the immune system reacts to strongly. Toxic shock syndrome is a medical emergency. Symptoms can include:
Toxic shock syndrome is a medical emergency
Toxic shock syndrome can lead to severe complications and be life threatening. If you suspect you or someone else has toxic shock syndrome, call 911 or your local emergency medical services.
Stasis dermatitis
Stasis dermatitis develops in areas of the body that have reduced blood flow, commonly in the feet and lower legs. While it can develop with aging, it may also indicate another health condition, such as heart or kidney disease. Symptoms can include:
Stasis ulcer
A stasis ulcer is a symptom of advanced stasis dermatitis. It also develops in areas of the body with reduced blood flow, such as the feet and lower legs.
Comments
Post a Comment